U.S. Study of Fibrocaps in Surgical Hemostasis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
ProFibrix, Inc.
ClinicalTrials.gov Identifier:
NCT01256164
First received: December 6, 2010
Last updated: June 6, 2014
Last verified: June 2014

December 6, 2010
June 6, 2014
December 2010
September 2011   (final data collection date for primary outcome measure)
Mean Time to Hemostasis (TTH) [ Time Frame: 0-10 minutes ] [ Designated as safety issue: No ]
Time to hemostasis recorded from the first application of study treatment until cessation of bleeding
Time to hemostasis of Fibrocaps plus gelatin sponge (USP), as compared to gelatin sponge (USP) alone [ Time Frame: 0-10 minutes ] [ Designated as safety issue: No ]
Time to hemostasis recorded from time 0 until cessation of bleeding
Complete list of historical versions of study NCT01256164 on ClinicalTrials.gov Archive Site
  • Safety [ Time Frame: 28 Days ] [ Designated as safety issue: Yes ]
    Number of participants with Adverse events and clinically-significant changes/findings on labs and physical examination as well as incidence of re-operation for bleeding at the TBS
  • Number of Subjects Achieving Hemostasis at 3 Minutes [ Time Frame: 3 minutes ] [ Designated as safety issue: No ]
  • Number of Participants Achieving Hemostasis at 5 Minutes [ Time Frame: 5 minutes ] [ Designated as safety issue: No ]
  • Number of Patients Achieving Hemostasis at 10 Minutes [ Time Frame: 10 minutes ] [ Designated as safety issue: No ]
  • Safety [ Time Frame: 28 Days ] [ Designated as safety issue: Yes ]
    Adverse events and clinically-significant changes/findings on labs and physical examination
  • Proportion of subjects achieving hemostasis within each group at 3, 5, and 10 minutes. [ Time Frame: 3, 5, and 10 minutes ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
U.S. Study of Fibrocaps in Surgical Hemostasis
A U.S. Phase 2, Randomized, Single-Blind, Controlled, Comparative Efficacy and Safety Study of Topical Fibrocaps™ and Gelatin Sponge (USP) in Surgical Hemostasis

The purpose of this study was to characterize the safety and hemostatic activity of topical Fibrocaps in surgical patients when control of mild to moderate bleeding by standard surgical techniques was ineffective and/or impractical.

This was a multi-center, prospective, randomized, single-blind, controlled, comparative efficacy and safety trial in 90 subjects undergoing spinal surgery, hepatic resection, specific soft tissue dissection, or peripheral vascular surgery, ((including peripheral artery bypass and arteriovenous graft formation for hemodialysis using either Polytetrafluoroethylene (PTFE) or native grafts)). Subjects were randomized in a 2:1 ratio to Fibrocaps + Gelfoam or Gelfoam on the day of surgery.

Use of the Fibrospray device was optional for spinal and vascular surgeries, but required for the general surgery procedures. All investigators using the Fibrospray device were trained on the correct and safe set-up and use of Fibrocaps and the Fibrospray device prior to participating in this clinical trial.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Supportive Care
Postoperative Hemorrhage
  • Device: Fibrocaps (fibrin sealant)
    Fibrocaps powder (max dose 1.5g) should be applied directly to the bleeding site or to the Gelfoam and then applied to the bleeding site. Re-application of 1.5 g of Fibrocaps is allowed.
    Other Name: Pro-0601
  • Device: Gelfoam
    An identified Target Bleeding Site (TBS) should be treated with application of Gelfoam followed by light manual pressure with a sterile gauze.
    Other Name: Gelfoam
  • Experimental: Fibrocaps + Gelfoam
    After identification of a Target Bleeding Site (TBS), topical Fibrocaps should be applied using the Fibrospray device for general surgeries; and either the Fibrospray device or direct application for spinal and vascular surgeries, followed by application of Gelfoam and manual pressure with sterile gauze.
    Intervention: Device: Fibrocaps (fibrin sealant)
  • Active Comparator: Gelfoam
    Treatment is Gelfoam followed by manual pressure with sterile gauze. If hemostasis is not achieved within 10 minutes of the Start Time,the subject should be considered a treatment failure and the surgeon should implement additional hemostatic measures.
    Intervention: Device: Gelfoam
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
70
October 2011
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • male or female 18 years of age or older
  • Subjects who are able and willing to provide written and signed informed consent
  • All subjects willing to use a medically accepted form of contraception from the time of consent to completion of all follow-up study visits
  • A life expectancy of at least one year

Intra-Operative inclusion criteria

  • Presence of mild or moderate bleeding/oozing when control by conventional surgical techniques, including but not limited to suture, ligature and cautery is ineffective or impractical
  • Absence of intraoperative complications other than bleeding which, in the opinion of the investigator, may interfere with the assessment of efficacy or safety
  • No intraoperative use of a topical hemostat containing thrombin
  • Approximate Target Bleeding Site surface area of no more than 100 square centimeters

Exclusion Criteria:

  • Pregnant or lactating women
  • Has a known intolerance to blood products or to Fibrocaps components
  • Unwilling to receive human blood products
  • Subject has a known allergy to porcine gelatin
  • Has a mental or physical condition that would, in the opinion of the investigator, place the subject at an unacceptable risk or render the subject unable to meet the requirements of the protocol
  • Currently participating or has participated in another clinical study involving another investigational agent within 4 weeks of the start of this trial, or is planning participation in another clinical trial during the 4 weeks after surgery
  • Has any clinically-significant coagulation disorder that may interfere with the assessment of efficacy or pose a safety risk to the subject according to the investigator
  • Aspartate Aminotransferase (AST) or Alanine aminotransferase (ALT) 3 times (or more) the upper limit normal range during screening, except for subjects undergoing liver resection surgery where there is no upper limit for these analytes due to the nature of their disease.
  • Platelets < 10 x 10^9 /L during screening
  • Activated partial thromboplastin time (aPTT) > 100 seconds during screening
  • International normalized ratio (INR)greater than 2.5 during screening
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01256164
FC-002
No
ProFibrix, Inc.
ProFibrix, Inc.
Not Provided
Study Director: Paul Frohna, MD, PhD ProFibrix, Inc.
ProFibrix, Inc.
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP